The National Pharmaceutical Pricing Authority‘s new policy on stent is welcome as it improves access and brings in transparency, but capping coronary stent prices may hurt manufacturers, according to Medanta Chairman Naresh Trehan.
first published: Feb 14, 2017 09:31 pm
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.

